Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 10Lymphoma, Non-Hodgkin 7Lymphoma, Follicular 6Lymphoma 5Lymphoma, Large B-Cell, Diffuse 3Recurrence 2Lymphoma, B-Cell, Marginal Zone 2Arthritis, Rheumatoid 2Off-Label Use 1Lymphoma, Mantle-Cell 1Leukemia, B-Cell 1Infections 1Hematologic Neoplasms 1Hematologic Diseases 1

Interventions

ziprasidone 1tocilizumab 1talquetamab 1idecabtagene vicleucel 1golimumab 1gilteritinib 1anifrolumab 1Zolpidem 1X-Rays 1Wearable Electronic Devices 1Watchful Waiting 1Warfarin 1Vital Signs 1Vecuronium Bromide 1Vancomycin 1Tumor Necrosis Factor Inhibitors 1Tranexamic Acid 1Tobramycin 1Spironolactone 1Sevelamer 1Rocuronium 1Rituximab 1Procalcitonin 1Piperacillin, Tazobactam Drug Combination 1Pentobarbital 1Oxycodone 1Nifedipine 1Nafcillin 1Molindone 1Methylprednisolone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Infections × Rituximab × Clear all
NCT06790420 2026-05-15

RITUXIMAB BS Intravenous Infusion 100mg・500mg [Pfizer] Post-marketing Database Study

Pfizer

Completed
2,703 enrolled 13 charts
Lymphoid

Infections, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡